Latest News

Aspire 2018

The 8th Congress of the Asia Pacific Initiative on Reproduction (ASPIRE 2018) will be held at Taipei International Convention Center, Taipei, Taiwan from 12 - 15 April 2018. Over the three days, the conference will consider the latest developments and their impact on the future of fertility preservation, embryology, andrology, clinical trials, PCOS, PGS, IVM, and related fields.

Planer will be exhibiting at Aspire 2018. If you are planning to visit the conference, don’t forget to come and see us on stand C53. We will be displaying the full range of Planer IVF products, including the CT37stax™ multi chamber incubator, the DATAssure™ wireless alarm and monitoring system as well as Shipslog3™ and PetriSense®.


Upper Egypt Assisted Reproduction Summit 2018

Mohamed Fawzy IVF Lab Director of Ibnsina and Banon IVF Centers Egypt
The Upper Egypt Assisted Reproduction Summit (UEARS) held in Cairo last February (21-23) saw the participation of 40 international speakers and 90 national ones for three days of scientific discussion with close to 1600 attendees from Egypt and overseas. With seven pre-congress workshops and a Consensus meeting, we looked into the micro environments, that can support the embryo in vivo and in vitro starting from how the human life began, navigating through the current and future techniques, including gene editing, with the current standards of embryo culture in between. New papers from 14 researches were presented for the first time during UEARS from young researchers.

Discussed in some detail was how the current standards of embryo culture have failed yet to make paradigm-shifting changes during the last 20 years, although some improvement has occurred. One of the elegant topics presented in the conference was from Catherine Racowsky of Harvard University who discussed the advantages of blastocyst transfer concluding that there remains a need for a robust evidence to support the superiority of blastocyst transfer compared with the cleavage-stage transfer. The new culture platforms that can improve the IVF outcomes were also discussed in a complete session.

In collaboration with The Egyptian Knowledge Bank, two research methodology workshops were conducted, navigating how reliable research should be robustly conducted and how a well conducted meta-analysis has to be done. These two research methodology workshops were arranged by Professor Ali Mahran from Asyut University and Dr Ola Laurence from the Egyptian Knowledge Bank, and delivered by Dr Léa Gagnon, PhD of Nature Research.

The conference had three parallel arms of infertility running throughout the three days. The gynaecology program arm, which was built by Drs Hazem Abdelghafar, Mohamed Sabry, Mohamed Yahya of Sohag University and Ahmed Nabil of Asyut University. The andrology program arm that was developed by Dr Ali Mahran. The embryology and genetics program arm, which was built by Mohamed Fawzy of Ibnsina and Banon IVF Centres, Egypt. The embryology arm had two parallel halls of lectures during the three days with a pre-congress four workshops. In the main program, Mohamed Fawzy delivered a talk navigating through his latest three publications discussing humidity, oxygen tension and temperature roles in human embryo culture. For the first time in RCT design, it has been shown that omitting humidity from some incubators was done with no robust evidence but with possible harm to the developing embryos and the downstream events. 

The UEARS 2018 lectures were generally considered to be of a very high scientific calibre. All UEARS Activities were well organized by the professional company Pure Spot Events Management; the closing remarks were focused on the concept of "no harm must be the goal in all IVF procedures and interventions". There is an open invitation to join UEARS in 2019 (Feb 20-22) which it is hoped will be of even higher quality and design.

Pictured here: Mohamed Fawzy, Scientific organiser of the embryology arm of UEARS, IVF Lab Director of Ibnsina and Banon IVF Centers Egypt

For further information on UEARS, please visit their website:



Managing risks in cryogenic storage

Over the last year or so there have been reports in the press on problems with samples stored in liquid nitrogen. Cryo storage is such a reliable method that it is often taken for granted - equipment is generally very robust and supply of liquid nitrogen, LN2, is typically very reliable. Patients as well as new entrants to the field are often surprised to learn that both the freezing of a sample, and its long-term storage, can be more complicated than they seem.

Many people, even those working in ART laboratories, remain unaware that specimens in cryogenic storage will suffer damage due to ice recrystallization when their temperature rises above -132°C (the ice transition point of water). And, the smaller the specimen the greater risk it is at, because its low thermal mass will allow its temperature to rise more quickly, and hence follow more closely, the rising external temperature, that of the storage environment. So the risk of ice recrystallization damage increases when comparing cryotubes to straws to vitrified embryo carrier devices.

Quality and Risk Management in the IVF Laboratory

In a definitive textbook on the subject on quality and risk management in the IVF lab, Drs Sharon and David Mortimer (pictured here) provide extensive background on the whole topic including explaining general principles applicable to managing risk in an Assisted Reproduction lab’s cryobank.    

In Chapter 8 “Managing Risk” there is a section on “Monitoring storage cryotanks” where they recount a personal experience of dealing with a degrading dewar and, based on that experience, provide a series of recommendations for routine good practice. And as an extension to the book, Dr David Mortimer has provided the following practical advice.

When using liquid storage in small cryotanks (e.g. up to 50 litres):

  • Top up the tanks regularly at quite strict weekly intervals – but before doing so measure and record in a logbook the level to which the LN2 has fallen. Performing weekly re-fillings, rather than more frequent top-ups, is not unreasonable when a typical tank (e.g. Taylor Wharton HC35) has a static working time of more than 11 weeks. Then use these measurements to create a control chart – a Shewhart chart - so that not only can unusually low levels be readily identified, but degrading performance of the tank will be seen as a series of decreasing levels of remaining LN2 prior to top-up.

  • In addition, tanks should be monitored for temperature and LN2 level with sensors connected to an automatic dial-out alarm system. Since the temperature of LN2 will always be -196°C the temperature sensor should be placed somewhere just below the typical level to which the LN2 will have fallen after a week of normal operational use and set to alarm at, say, -160°C. The LN2 level sensor should be located a short distance above where the uppermost specimen is held in storage.

When using liquid storage in large cryotanks of say 150 litres and more:

  • These tanks must be connected to a large LN2 supply so they can operate on auto-fill.
    Note: Ideally the cryotank controller should be “smart” and able to communicate with external monitoring software to allow logging of the amount of LN2 used; these data can then be used to generate an alarm should usage increase beyond a certain limit. An example of this would be the MVE TEC 3000 controller from Chart Industries combined with Planer’s DATAssure software.

  • Temperature and LN2 level sensors should be installed using the same principles as with small tanks and connected to an automatic dial-out system.


When using vapour storage in smaller dewars manual monitoring of the LN2 level is impractical, and a combination of LN2 level and temperature sensors should be used:

Locate the temperature sensor a good distance above the uppermost specimen in storage and have it alarm when the measured temperature falls below -140°C (which is considered to be the limit for safe vapour storage).

  • Locate the LN2 level sensor at the manufacturer’s recommended minimum LN2 level for safe operation of the cryotank.
  • When using vapour storage in large dewars the same principles for positioning the temperature and LN2 level sensors as in small dewars apply. However, because these tanks operate on auto-fill their regular consumption of LN2 should be monitored as described for large liquid storage dewars.

At Planer we are keen to promote safe cryo storage. As well as controlled rate freezers we sell vessels, alarm systems, monitoring systems and cryo transport loggers through our distributors available all over the world.

For further information
For Planer Monitoring:
For ‘Quality and Risk Management in the IVF Laboratory’:










45 years - still pioneers

45 years logoPlaner plc celebrates 45 years
In 2018 Planer plc, formerly known as Planer Products, will be celebrating 45 years of designing, manufacturing, selling and supporting products for a variety of technical uses throughout the world. The company sprung from GV Planer Ltd., founded in the 1950s, primarily a design and research consultancy making one off products for research institutions. It was some of these earlier research products that were the foundations of the equipment that Planer plc went on to develop into commercially viable machines. These continued to evolve over the 45 years into the products we manufacture and sell today.

Slow freezing pioneers
The first birth from a frozen bovine embryo was reported in 1972 - using a very early Planer machine. Professors Rawson and Wilmut pioneering the animal husbandry field. With its successful development and the use of products for controlled rate freezing, the company received the Queen's Award for Technology and also awards from the British DTI for Innovation and Good Practice in Micro-electronics and achieved approval and for the demanding standards of medical device manufacture: ISO13485:2012 & Medical Devices Directive, Annex 11 93/42/EEC: LRQA. ISO 9001:2008.

The use of controlled rate freezers widens
IVF labs were the initial market but later hospitals and researchers found they needed programmable freezing for many types of cells – in areas such as cord blood banking, bone marrow transplants, botanicals, semen, oocytes, skin, ovarian tissue, heart valves and blood vessels. Planer Controlled Rate Freezers continue to be at the forefront of many of today’s scientific breakthroughs using cryopreserved cells.

Forty two years ago in 1976 we conceived our very first incubator whilst collaborating with the then UK Department of Health and Social Services in the production of a new form of anaerobic incubator as an alternative to the prevailing jar system for the isolation of anaerobes from clinical material. The prototype machine was built around 1980 and was tested by a team led by Dr Berry from the Department of Microbiology at St Thomas's Hospital Medical School London, SE1 in 1981. The Planer range of CO2 incubators has since been developed further with the introduction of the very successful BT37 in 2009 and the new CT37stax multi chamber incubator in 2017.

Throughout 2018, we plan to run a series of articles and events to celebrate our 45 years of working with and supporting scientists and healthcare professionals who use our equipment to preserve, protect and nurture all types of cells in many important applications throughout the world.

Pictured here: Professor David Pegg with a Planer freezer in the 1970s.






Preservation of Cells: A Practical Manual by Allison Hubel

Professor Allison HubelA new book has just been published by Professor Allison Hubel of the University of Minnesota. It aims to provide readers interested in cryo bio banking with the tools needed to develop or debug a preservation protocol for cells. The core structure and content of the text grew from a professional short course that she has offered at the Biopreservation Core Resource over the last 10 years. The text describes, step by step, the individual elements of a protocol, including the relevant scientific principles for each phase. It can be used by anyone who is involved in cell preservation - including those not expert in the freezing of cells; it does provide the scientific basis for those that want to understand the basis for the protocol.

The book covers pre-freeze Processing and Characterization; Formulation and Introduction of Cryopreservation Solutions; Freezing Protocols; Storage and Shipping of Frozen Cells; Thawing and Post Thaw Processing; Post-thaw Assessment; and Algorithm driven Protocol Optimisation. Professor Hubel explains the reasons behind every step in the development of a preservation protocol and the scientific principles behind them and provides alternative modes of preservation for when conventional methods of cryopreservation are not appropriate for a given cell type or application.

Preservation of Cells A Practical Manual by Allison HubelMammalian cells have become modern workhorses capable of a variety of applications, such as in production of therapeutic proteins, viral vaccines, antibodies and therapeutic agents. Cells that are to be used therapeutically must be properly stored to meet the safety and quality control testing prior to release of the cells. There are a variety of methods that can be used to preserve cells depending upon downstream application.  Specific practices are intended to improve both the outcome and the reproducibility of preservation protocols. The preservation toolkit is used to develop fit-for-purpose preservation protocols. Each element of a protocol is based on scientific principles and those principles are explained and can be used to rationally design that particular step to achieve the desired downstream use of the cell. The influence of processing procedures on the health of cells prior to cryopreservation and strategies to mitigate stress on cells is explained along with the formulation and introduction of cryopreservation solutions.

There is a specific chapter on controlled rate freezing with all the steps of a controlled rate freezing protocol and guiding principles for design of that step are given. Also described is a process for transferring units from a controlled rate freezer to a storage unit and there are examples showing good and bad freezing curves. Prof Hubel also covers storage and shipping of frozen cells, processing, assessment, protocol optimisation and the cryopreservation of endothelial cells in suspension, peripheral blood mono nuclear cells from whole blood, human adipose stem cells, red blood cells, oocytes and more.

Preservation of Cells: A Practical Manual is an important book for researchers, laboratory technicians and students in cell biology, stem cell biology, tissue engineering, and regenerative medicine. It is also useful to cell bankers, regenerative medicine, biomarker discovery or precision medicine companies, and cell therapy labs, blood bankers, biobankers, and biotechnology companies.

For further information:
Prof Allison Hubel
Preservation of Cells: A Practical Manual (John Wiley & Sons, Inc., Print ISBN: 9781118989845)




Progress on a bio-artificial liver

A bio-artificial liver - a BAL - is used as an extra-corporeal organ designed to aid the function of the liver in patients with acute failure and University College London's team are working on one where liver cells are encapsulated in alginate. The challenge as a clinical product is related to immediate availability, because of the unpredictability of disease progression in acute liver failure.

The aim of a recent study, presented at the Society of Low Temperature Biology annual meeting by Eloy Erro, Joana da Silva (both pictured here) et al, was to achieve BAL biomass cryopreservation with different systems for post-thaw culture and recovery, aiming at an off-the-shelf product. HepG2 cells were encapsulated in 1% alginate solution, producing ~500µm beads which were encapsulated and cultured for 12-14 days in a fluidised bed bio reactor (FBB) to obtain sufficient biomass.

Cryopreservation of >1L of alginate cell beads was achieved in a cryo-bag using our controlled rate freezer Kryo 750 and DMSO was used as cryoprotectant with an ice nucleator.

The team concluded that successful cryopreservation of encapsulated liver cell spheroids on a large scale, at 16-48% of a total human liver size (the biomass of 30% liver cell numbers is the likely requirement for such a bio-artificial liver) represented the correct order of magnitude and provided sufficient post-thaw recovery. They also found the process could be easily scalable in freezing bags using the Kryo750 and the same fluidised-bed bioreactor for cell recovery. The use of micro-organoids within an alginate matrix proved an interesting choice for large-scale cryopreservation avoiding problems associated with large tissue freezing. However a more rapid recovery would be ideal, and the team is exploring improvements.

Further information:
Poster - The BAL Team :
Planer's controlled rate freezer:
To download PDF of poster, please click here.

bio artificial liver poster ucl




New controlled rate freezer at Cell Tech Pharmed

controlled rate freezers at CellTech Pharmed

Professor Nasser Agdami
Prof Nasser Aghdami, a user of Planer freezers when he was at Iran's Royan Institute, recently helped to set up a new company Cell Tech Pharmed to meet an increasing demand for stem cell therapy. The focus on several distinct areas - systemic diseases with an underlying inflammatory and immunologic etiology, cardiac and vascular diseases, orthopaedic diseases of the knee, ankle and pelvis where cell therapy products can be locally administered, improving outcomes of bone marrow transplantation and also skin augmentation where current methods are ineffective.

Embryonic stem cells or pluripotent stem cells can differentiate into any cell in the body. Because stem cells in the umbilical cord are less developed than adult stem cells, they don't have to be "matched" as stringently to a patient's human leukocyte antigen, or HLA, type. In the USA for example more than 80,000 unrelated bone marrow and umbilical cord blood transplants have been facilitated since 1987.

Embryonic stem cells or pluripotent stem cells can differentiate into any cell in the body. Because stem cells in the umbilical cord are less developed than adult stem cells, they don't have to be "matched" as stringently to a patient's human leukocyte antigen, or HLA, type. In the USA for example more than 80,000 unrelated bone marrow and umbilical cord blood transplants have been facilitated since 1987.

Planer Kryo 360 Controlled Rate Freezer at CellTech PharmedThe new company has the technical help and financial support of Dr Aghdami's old employer, the Royan Institute, along with the commercial backing of the Barakat Pharmed Company, a large pharmaceutical holding company.  In the pharma world, quality is of course paramount - the Barakat group complies with all common pharmaceutical standards such as the FDA, WHO, EMEA. Likewise in Cell Tech Pharmed who use one of our precision slow freezers, a Kryo 360, (pictured here) for their cell freezing.


Professor Brian Grout speaks at Stem Cell Users Group Meeting

We were pleased to be one of the commercial sponsors of this important meeting at Kings College Hospital, London, bringing together more than 60 stem cell practitioners to share knowledge and experiences and discuss current issues and difficulties. For this group, cryopreservation is a key enabling technology contributing to advances in both basic research and clinical practice. Consequently, a strong understanding of the principles underlying cryopreservation protocols is important to group members and we were happy to be able to support Professor Brian Grout*, a widely experienced cryobiologist and recent Chair of the Society for Low Temperature Biology, to contribute to the meeting.

Brian presented the audience with a cryobiologist’s view of the cryochain central to a stem cell user’s activities, moving from cell preparation to end use in the laboratory or on the clinical front-line. The intention was to present the pitfalls experienced by the audience in a cryobiological context and to point out where stronger biological understanding can be used to eliminate costly, and typically unintended, poor practice. Throughout, the concept was that all the cryopreservation team members need to be aware of the biological issues, especially where frozen material has to be recovered by separate groups e.g. clinicians, with the expectation of reproducible, high performance of the frozen product.

In particular, a good deal of attention was given to the benefits of controlled ice nucleation and the risks of damaging temperature rise to samples that are lifted up into the neck of storage vessels when searching for specific samples. Further, the potentially lethal effects of poorly controlled thawing protocols were examined together with some of the risks of microbial contamination of the cryogen in storage vessels and transit shippers.  The need for strong, supporting biological knowledge to underpin successful cryopreservation was underlined and also the continuing need for sustained research and developments in technology; this, to strengthen the level of control available to those using stem cell cryopreservation as a near-routine tool. Positive feedback from the meeting was strong and we are looking forward to continuing our links with this stem cell users group in the coming year.

*Emeritus Professor, Life Sciences, Copenhagen University

News Stories - 2019

News Stories - 2018

News Stories - 2017